Publications

130 results

130 results

2024

Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J-R, Muhlich J, Mittendorf E, Santagata S, Guerriero J, et al. Quality control for single cell analysis of high-plex tissue profiles using CyLinter. bioRxiv. 2024.

Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J-R, Muhlich J, Mittendorf E, Santagata S, Guerriero J, et al. Quality control for single cell analysis of high-plex tissue profiles using CyLinter. bioRxiv. 2024.

Guerriero J, Lin J-R, Pastorello R, Du Z, Chen Y-A, Townsend M, Shimada K, Hughes M, Ren S, Tayob N, et al. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024;10(1):2.

Guerriero J, Lin J-R, Pastorello R, Du Z, Chen Y-A, Townsend M, Shimada K, Hughes M, Ren S, Tayob N, et al. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024;10(1):2.

Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates. Clinical Cancer Research. 2024;30(7):1281–1292.

Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates. Clinical Cancer Research. 2024;30(7):1281–1292.

Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Jadeja S, Murphy G, Nirmal A, Lian C, Sorger P, et al. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study. The Journal of investigative dermatology. 2024:S0022–202X.

Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Jadeja S, Murphy G, Nirmal A, Lian C, Sorger P, et al. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study. The Journal of investigative dermatology. 2024:S0022–202X.

Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J-R, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer. Journal of Clinical Oncology. 2024;42(11):1311–1321.

Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J-R, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer. Journal of Clinical Oncology. 2024;42(11):1311–1321.

2023

Lin J-R, Wang S, Coy S, Chen Y-A, Yapp C, Tyler M, Nariya M, Heiser C, Lau K, Santagata S, et al. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Cell. 2023;186(2):363–381.

Lin J-R, Wang S, Coy S, Chen Y-A, Yapp C, Tyler M, Nariya M, Heiser C, Lau K, Santagata S, et al. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Cell. 2023;186(2):363–381.

Gaglia G, Burger M, Ritch C, Rammos D, Dai Y, Crossland G, Tavana S, Warchol S, Jaeger A, Naranjo S, et al. Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. Cancer Cell. 2023;41(5):871–886.

Gaglia G, Burger M, Ritch C, Rammos D, Dai Y, Crossland G, Tavana S, Warchol S, Jaeger A, Naranjo S, et al. Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. Cancer Cell. 2023;41(5):871–886.

Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Murphy G, Nirmal A, Lian C, Sorger P, LeBoeuf N. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence. bioRxiv. 2023:2023–04.

Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Murphy G, Nirmal A, Lian C, Sorger P, LeBoeuf N. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence. bioRxiv. 2023:2023–04.

Lecky E, Mukherji A, German R, Antonellis G, Lin J-R, Yorsz M, McQueeney K, Ryan J, Ng K, Sicinska E, et al. Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells. Science Advances. 2023;9(25):eadg4128.

Lecky E, Mukherji A, German R, Antonellis G, Lin J-R, Yorsz M, McQueeney K, Ryan J, Ng K, Sicinska E, et al. Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells. Science Advances. 2023;9(25):eadg4128.

Lin J-R, Chen Y-A, Campton D, Cooper J, Coy S, Yapp C, Tefft J, McCarty E, Ligon K, Rodig S, et al. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. Nature cancer. 2023;4(7):1036–1052.

Lin J-R, Chen Y-A, Campton D, Cooper J, Coy S, Yapp C, Tefft J, McCarty E, Ligon K, Rodig S, et al. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers. Nature cancer. 2023;4(7):1036–1052.

Creason A, Egger J, Watson C, Sivagnanam S, Chin K, MacPherson K, Lin J-R, Chen Y-A, Johnson B, Feiler H, et al. Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers. bioRxiv. 2023:2023–09.

Creason A, Egger J, Watson C, Sivagnanam S, Chin K, MacPherson K, Lin J-R, Chen Y-A, Johnson B, Feiler H, et al. Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers. bioRxiv. 2023:2023–09.

Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, et al. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer. Cancer Research. 2023;83(19):3284–3304.

Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, et al. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer. Cancer Research. 2023;83(19):3284–3304.